CRISPR Therapeutics (CRSP) Submits Trial Application for CRISPR Gene-Edited Therapy, CTX001 – StreetInsider.com
|
CRISPR Therapeutics (CRSP) Submits Trial Application for CRISPR Gene-Edited Therapy, CTX001
StreetInsider.com CRISPR also plans to file an Investigational New Drug Application for CTX001 to treat sickle cell disease with the United States Food and Drug Administration in 2018. “β-thalassemia is a devastating disease that requires serious and chronic medical … |
